NCT07336862RecruitingPhase 1/2
Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Severe Obesity: A Prospective, Multicenter Cohort Study
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 29 Sept 2025
- Start date
- 1 Jan 2024
- Primary completion date
- Dec 2027
- Lead sponsor
- China-Japan Friendship Hospital
- Diseases
- Obesity
- NCT number
- NCT07336862
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 200
- From 1 Jan 2024 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively
- Prior bariatric surgery: History of any metabolic/bariatric surgical procedure
- Non-indicated candidates: Patients not meeting standard bariatric surgery indications
Other illness
- Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak)
Lab values
- Significant comorbidities:
- Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR \<30 mL/min/1.73m²)
- Active malignancy (except non-melanoma skin cancers)
- Autoimmune disorders requiring immunosuppression
- Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression)
Who the study is looking for
- Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG)
- obesity:BMI ≥35 kg/m²
- Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria
- Age range: 18-60 years (inclusive)
- Informed consent: Willing participation with documented consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China-Japan Friendship Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.